Bridgebio Oncology Therapeutics Stock Return On Equity
| BBOT Stock | 12.29 0.23 1.84% |
BridgeBio Oncology's fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting BridgeBio Stock price.
| Last Reported | Projected for Next Year | ||
| Return On Equity | (0.35) | (0.34) |
BridgeBio | Return On Equity | Build AI portfolio with BridgeBio Stock |
BridgeBio Oncology Therapeutics Company Return On Equity Analysis
BridgeBio Oncology's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current BridgeBio Oncology Return On Equity | -0.34 |
Most of BridgeBio Oncology's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BridgeBio Oncology Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
BridgeBio Return On Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for BridgeBio Oncology is extremely important. It helps to project a fair market value of BridgeBio Stock properly, considering its historical fundamentals such as Return On Equity. Since BridgeBio Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BridgeBio Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BridgeBio Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
BridgeBio Total Stockholder Equity
Total Stockholder Equity |
|
BridgeBio Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BridgeBio Oncology's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BridgeBio Oncology could also be used in its relative valuation, which is a method of valuing BridgeBio Oncology by comparing valuation metrics of similar companies.BridgeBio Oncology is currently under evaluation in return on equity category among its peers.
BridgeBio Oncology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, BridgeBio Oncology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BridgeBio Oncology's managers, analysts, and investors.Environmental | Governance | Social |
BridgeBio Fundamentals
| Current Valuation | 856.64 M | ||||
| Shares Outstanding | 79.2 M | ||||
| Shares Owned By Insiders | 24.04 % | ||||
| Shares Owned By Institutions | 51.02 % | ||||
| Number Of Shares Shorted | 1.5 M | ||||
| EBITDA | (80.66 M) | ||||
| Net Income | 7.6 M | ||||
| Total Debt | 5.71 M | ||||
| Book Value Per Share | (403.34) X | ||||
| Cash Flow From Operations | (763.82 K) | ||||
| Short Ratio | 2.07 X | ||||
| Earnings Per Share | (1.11) X | ||||
| Target Price | 24.2 | ||||
| Number Of Employees | 81 | ||||
| Market Capitalization | 1.01 B | ||||
| Total Asset | 194.42 M | ||||
| Retained Earnings | (3.73 M) | ||||
| Working Capital | 139.11 M | ||||
| Net Asset | 194.42 M |
About BridgeBio Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BridgeBio Oncology Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BridgeBio Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BridgeBio Oncology Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for BridgeBio Stock Analysis
When running BridgeBio Oncology's price analysis, check to measure BridgeBio Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BridgeBio Oncology is operating at the current time. Most of BridgeBio Oncology's value examination focuses on studying past and present price action to predict the probability of BridgeBio Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BridgeBio Oncology's price. Additionally, you may evaluate how the addition of BridgeBio Oncology to your portfolios can decrease your overall portfolio volatility.